Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDL79K
|
|||
| Drug Name |
XMT-1592
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1/2 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1] | ||
| Company |
Mersana Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/phosphate cotransporter 2B (SLC34A2) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04396340) First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Mersana Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.